Key facts
- Imbria Pharmaceuticals’s last known valuation is $131.7M (Dec 2025).
- It has raised $151.9M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($66.7M) in Dec 2025.
- Notable investors include RA Capital Management, Catalio Capital Management, SV Health Investors, Deep Track Capital, AN Ventures — 9 tracked in total.
- Imbria Pharmaceuticals has filed 2 Form Ds with the SEC since 2020, most recently Apr 2025 ($59.2M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Imbria Pharmaceuticals
Funding rounds
2 roundsAbout Imbria Pharmaceuticals
Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders. The company focused on restoring or improving the cell's ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction, enabling healthcare providers to provide medicine by altering the cellular metabolism and mitochondrial function.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 10
- Website
- imbria.com/
- Ownership
- Privately Held (backing)
Imbria Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imbria Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imbria Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.